www.stryker.com
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C.
20549
________________________
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
|
Date of Report (Date of earliest event
reported) May 5, 2009
|
|
|
|
|
|
|
|
|
|
|
|
|
|
STRYKER CORPORATION
|
|
(Exact name of registrant as specified
in its charter)
|
|
|
|
|
|
Michigan
|
0-9165
|
38-1239739
|
|
(State or other jurisdiction
|
(Commission File Number)
|
(IRS Employer
|
|
of incorporation)
|
|
Identification No.)
|
|
|
|
|
|
2825 Airview Boulevard, Kalamazoo, Michigan
|
49002
|
|
(Address of principal executive offices)
|
(Zip Code)
|
|
|
|
|
|
Registrant's telephone number, including
area code 269.385.2600
|
|
|
|
|
|
|
|
|
Check the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions:
[ ] Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[ ] Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[ ]
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange
Act (17 CFR 240.14d-2(b))
[ ]
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange
Act (17 CFR 240.13e-4(c))
Stryker Corporation (NYSE:SYK) received a warning letter dated May 5, 2009 from the U.S.
Food and Drug Administration (FDA) related to compliance issues for one of its
craniomaxillofacial (CMF) implant products that was previously sold through its
CMF distribution facility in Portage, Michigan. The Company is in the process
of responding to the FDA regarding this matter.
On May 7, 2009, the Company received a subpoena from
the Attorney General of New Jersey requesting various documents related to the
financial interests and arrangements of physicians participating in certain
clinical trials for or on behalf of the Company. The Company is evaluating the
scope of the subpoena and its response. The Attorney General of New Jersey
reportedly issued similar subpoenas to other major medical device manufacturing
companies.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of
1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
STRYKER CORPORATION
(Registrant)
May 11, 2009 /s/ CURT R. HARTMAN
Date Curt
R. Hartman
Vice President and Chief Financial Officer
